Cytokinetics, Incorporated (CYTK) vs TG Therapeutics, Inc. (TGTX)

Cytokinetics, Incorporated and TG Therapeutics, Inc. are both Biotechnology companies. Cytokinetics, Incorporated and TG Therapeutics, Inc. are of similar size ($9.0B and $8.8B). Cytokinetics, Incorporated has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 18.9×. TG Therapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against −21.1%. TG Therapeutics, Inc. has the higher net margin (55.2% vs −1,321.1%) and the higher return on invested capital (10.7% vs 0.00%). Across the 17 metrics below, TG Therapeutics, Inc. leads on 12 and Cytokinetics, Incorporated on 5.

Valuation

Metric CYTK TGTX Biotechnology median
P/E n/m 18.89 7.88
P/S 126.21 10.18 11.47
P/B n/m 13.48 2.52
Price to free cash flow n/m 468.33 21.16
EV/EBITDA n/m 61.31 0.74
EV/Sales 125.94 10.43 10.73
Earnings yield (11.17%) 5.29% (28.84%)
Free cash flow yield (6.80%) 0.21% (23.03%)

Profitability

Metric CYTK TGTX Biotechnology median
Gross margin 87.97% 82.37% 65.16%
Operating margin (1,046.12%) 17.05% 0.00%
Net margin (1,321.12%) 55.22% 0.00%
Free cash flow margin (858.16%) 2.17% 0.00%
Return on equity 329.76% 100.28% (57.72%)
Return on assets (56.76%) 37.70% (49.22%)
Return on invested capital 0.00% 10.69% 0.00%

Growth

Metric CYTK TGTX Biotechnology median
Revenue growth (TTM) (21.07%) 76.08% 5.64%
EPS growth (last fiscal year) (24.33%) 1,746.67% —
Revenue growth, 5-year CAGR 9.54% 426.73% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CYTK TGTX Biotechnology median
Debt to equity (6.61) 1.23 0.00
Current ratio 6.66 4.27 4.73
Net debt to EBITDA (0.46) 0.86 0.96

Dividend

Metric CYTK TGTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CYTK TGTX Biotechnology median
Market cap 8.98b 8.80b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack